Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial

BACKGROUND: Calcium release-activated calcium (CRAC) channel inhibitors block proinflammatory cytokine release, preserve endothelial integrity and may effectively treat patients with severe COVID-19 pneumonia. METHODS: CARDEA was a phase 2, randomized, double-blind, placebo-controlled trial evaluati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruen, Charles, Al-Saadi, Mukhtar, Michelson, Edward A., Tanios, Maged, Mendoza-Ayala, Raul, Miller, Joseph, Zhang, Jeffrey, Stauderman, Kenneth, Hebbar, Sudarshan, Hou, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992417/
https://www.ncbi.nlm.nih.gov/pubmed/35395943
http://dx.doi.org/10.1186/s13054-022-03964-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992417/
https://www.ncbi.nlm.nih.gov/pubmed/35395943
http://dx.doi.org/10.1186/s13054-022-03964-8

Ejemplares similares